Paclitaxel (PAC) treatment is associated with persistent, debilitating neuropathic pain that affects the hands and feet. Female sex and biological stress responsivity are risk factors for persistent pain, but it is unclear whether these important biologically based factors confer risk for PAC-induced neuropathic pain. To determine the relative contributions of sex and hypothalamic-pituitaryadrenal (HPA)-axis stress responsivity to PAC-induced mechanical hypersensitivity, we employed a PAC protocol consisting of three, 2-week cycles of every-other-day doses of PAC 1 mg/kg versus saline (Week 1) and recovery (Week 2), totaling 42 days, in mature male and female Fischer 344, Lewis, and Sprague Dawley (SD) rats, known to differ in HPA axis stress responsivity. Mechanical sensitivity was operationalized using von Frey filaments, per the up-down method. Among PAC-injected rats, SD rats exhibited significantly greater mechanical hypersensitivity relative to accumulative PAC doses compared to Fischer 344 rats. Lewis rats were not significantly different in mechanical hypersensitivity from SD or Fischer 344 rats. At the end of the protocol, PAC-injected SD rats exhibited profound mechanical hypersensitivity, whereas the PAC-injected Fischer 344 rats appeared relatively resilient to the long-term effects of PAC and exhibited mechanical sensitivity that was not statistically different from their saline-injected counterparts. Sex differences were mixed and noted only early in the PAC protocol. Moderate HPA axis stress responsivity may confer additional risk for the painful effects of PAC. If these findings hold in humans, clinicians may be better able to identify persons who may be at increased risks for developing neuropathic pain during PAC therapy.
determine whether there are sex or hypothalamic-pituitaryadrenal (HPA) axis stress responsivity differences in CIPN are sparse. Prior preclinical work that employed a variety of nerveinjury pain models reported differential pain response based on known differences in HPA axis stress responsivity (Fecho & Valtschanoff, 2006; Herradon et al., 2007; Shir et al., 2001) .
Few preclinical studies have explored either sex or HPA axis stress responsivity differences in PAC-induced neuropathic pain. Much of the early preclinical work to determine PAC-induced mechanical hypersensitivity trajectories in rodents involved only male rats (e.g., Authier, Gillet, Fialip, Eschalier, & Coudore, 2000; Dina et al., 2001; Flatters & Bennett, 2004 Polomano, Mannes, Clark, & Bennett, 2001) , with a few other studies using only female rats (e.g., Cavaletti et al., 1997; Cavaletti, Tredici, Braga, & Tazzari, 1995; Cliffer et al., 1998) . Among the few rodent studies of PAC-induced mechanical hypersensitivity that tested sex differences, results were mixed. In two studies that employed male and female Sprague Dawley (SD) rats, authors reported no sex differences in PAC-induced mechanical hypersensitivity (Hwang, Kim, Kim, Kwon, & Kim, 2012; Kozachik, Opp, & Page, 2015) . However, in a study of 10 inbred mouse strains, authors reported that male mice, as compared to female mice, demonstrated significantly greater PAC-induced mechanical hypersensitivity and that the DBA/2J strain demonstrated an amplified mechanical hypersensitivity response to PAC (4 mg/kg, accumulative), whereas the C57BL/6J strain demonstrated resilience against the effects of PAC until Day 21 post-PAC injections (Smith, Crager, & Mogil, 2004) .
The DBA/2J and C57BL/6J strains of mice differ in HPA axis stress responsivity. In one study, the strains exhibited statistically equivalent baseline corticosterone levels, but the DBA/2J strain had a significantly greater corticosterone response to uncontrollable foot shock (Shanks, Griffiths, Zalcman, Zacharko, & Anisman, 1990) . To our knowledge, there are no reports of clinical or preclinical research of HPA axis stress responsivity and its relationship to PAC-induced neuropathic pain (clinical reports) or mechanical hypersensitivity (preclinical research) . The goal of the present study was to determine whether there are sex or HPA axis stress responsivity differences in PAC-induced mechanical hypersensitivity. We employed male and female rats from the inbred Fischer (F) 344 and Lewis (LEW) strains to take advantage of their naturally occurring HPA axis hyper-and hypo-stress responsivity, respectively (Sternberg et al., 1992) , and the outbred SD strain known to demonstrate a more moderate HPA axis stress responsivity (Page, Opp, & Kozachik, 2014) . Given the abundant clinical literature that supports female sex and an anxious temperament as risks for persistent pain, we hypothesized that female Fischer 344 rats would exhibit significantly greater PAC-induced mechanical hypersensitivity.
Material and Method Study Design
This experimental study employed a 3 Â 2 Â 2 factorial design, with strain (F344, LEW, and SD), drug (PAC vs. 0.9% saline), and sex as main effects to determine their independent and combined/interaction effects on PAC-induced mechanical hypersensitivity. Briefly, rats underwent tail-tip clip for baseline corticosterone, rested for no less than 48 hr, and then were exposed to the elevated plus maze (EPM) with a 30-min poststress tail-tip scab removal for plasma corticosterone. Rats were also habituated to the testing room for 15, 20, and 30 min over consecutive days and then habituated for 30 min followed by von Frey hair (VFH) testing for up to 3 days. Rats with bilateral 50% paw withdrawal threshold (PWT) ! 10 g on the last day of preprotocol testing were entered into the study. On protocol Days 1, 3, 5, and 7, animals were injected (intraperitoneal [ip]) with either PAC (1 mg/kg) or 0.9% saline (VEH) just prior to lights on. At 6 hr post lights on, rats underwent VFH testing. On protocol Days 8-14, the 7-day intercycle/recovery period, rats were not injected, but they did undergo VFH testing. We repeated this 14-day cycle twice to more closely model a clinical chemotherapy protocol that a cancer patient might undergo (Kozachik et al., 2015) . VFH testing occurred through Day 42. Figure 1 depicts the time course for all procedures. Table 1 shows the assignment of rats to treatment group by sex and strain.
Procedures
Animals. We bred the 82 rats (n ¼ 27 F344, n ¼ 26 LEW, and n ¼ 29 SD) used for this study in-house to eliminate the impact of institutionalized rearing, shipping, and acclimatization into a new environment. We purchased breeders from Harlan Sprague-Dawley (Indianapolis, IN) and acclimatized them for a minimum of 21 days before breeding. Pups were weaned at 21 days of age and housed with same-sex littermates. Rats were entered into the study at 14-16 weeks of age, at which time they were individually housed in standard plastic cages with bedding. Standard rat chow and water were available ad libitum. We maintained rats on a 12:12-hr light-dark cycle, with lights on at 1300 hr, until after we obtained plasma for baseline and poststress corticosterone. We then transitioned rats to lights on at 0800 via a 1-hr per day phase advance in light cycle. Rats were housed at an environmental temperature of 23 C (+ 2 ) and humidity of 40% (+ 5%).
Corticosterone assessment. We accomplished baseline blood withdrawal via tail-tip clip during the latter half of the dark phase. Briefly, a rat was removed from its cage, wrapped gently in a towel, and lightly restrained. A small nick was made at the tip of the tail using a scalpel blade and the tail gently ''milked'' caudally until 300-μl blood was collected in a micro-centrifuge tube with heparin, 20 units/ml. We completed this procedure within 3 min of approaching the cage, beyond which time the stress of the procedure would be evident (Vahl et al., 2005) . Post moderate stress exposure blood withdrawal was accomplished by gentle tail-scab removal at 30 min following the completion of the 5-min EPM exposure. Immediately after withdrawal, blood for plasma corticosterone was centrifuged, aliquoted, and stored at À80 C. Baseline and poststress corticosterone levels were measured in duplicate using corticosterone enzyme immunoassay kits from Enzo Life Sciences (Plymouth Meeting, PA).
Behavioral testing. The EPM is 50 cm above the floor, both open and closed arms are 50 Â 10 cm, and the closed-arm walls are 40 cm high (Columbus Instruments, OH). The EPM testing was conducted during the dark phase in a room illuminated by a red light. A single animal was placed at the intersection of the closed and open arms, facing the open arm, and videotaped for the 5-min test. EPM behaviors counted included the numbers of open-arm entries, closed-arm entries, rears, and stretchedattend postures. We calculated tallies for the total time spent on open arms and the total time spent on closed arms. Immediately after removal from the EPM, rats were returned to their home cage. The EPM has been well validated as a stressinducing apparatus. Pellow, Chopin, File, and Briley (1985) found that, compared to cage-control animals, animals that underwent a 5-min exposure to the EPM exhibited significantly increased corticosterone levels, while Page, Opp, and Kozachik (2014) found that a 5-min exposure to the EPM resulted in significantly increased corticosterone levels compared to baseline.
von Frey testing for mechanical sensitivity. We operationalized mechanical sensitivity using VFH testing. We conducted VFH testing during the latter 6 hr of the light phase using eight von Frey filaments with logarithmically incremental bending forces, ranging from 0.45 to 16.69 g, via the up-down method (Dixon, 1980) . Animals were placed inside small, lidded plexiglass boxes on raised wire mesh. The von Frey filament was applied with bending force for 5-7 s to the hind paw plantar surface between the footpads, beginning with the fourth strongest filament. If a brisk paw withdrawal was elicited, the next weaker von Frey filament was applied. In the absence of such a response, the next stronger von Frey filament was applied. This procedure yielded a range of four to nine applications per paw and resulted in the fewest perturbations of the paw versus other testing methods. Given reported changes in response to VFH testing when animals were distracted by grooming (Callahan, Gil, Levesque, & Mogil, 2008) , we waited for the rats to cease grooming before we presented a von Frey filament. We calculated the 50% PWT according to the methods of Dixon (1980) , and reductions in 50% PWT values translate to increases in mechanical sensitivity. We calibrated the von Frey filaments between each replicate assay.
PAC preparation and administration. We developed the PAC protocol in our lab to model the human experience of undergoing chemotherapy and used it in a companion study (Kozachik et al., 2015) . Briefly, PAC (Henry Schein, NY) was supplied in multiuse vials at a concentration of 6 mg/ml. Just prior to ip administration, we diluted PAC to a final concentration of 1 mg/ml in a bacteriostatic 0.9% saline. For each 2-week chemotherapy cycle, rats were injected with PAC (1 mg/kg) every other day for four doses, followed by a 7-day recovery period that began the day after the fourth dose of PAC. Rats underwent three cycles of PAC for a total dose of 12 mg/kg. This PAC dose is equivalent to a clinically relevant dose for humans (Scripture, Figg, & Sparreboom, 2005) . Given the cytotoxic nature of PAC and the urinary and fecal excretion of the active drug and its metabolites (Monsarrat et al., 1990) , we handled rats, cages, and bedding as biohazards.
Animal health assessment during the PAC protocol. We weighed rats 3 times per week throughout the protocol and visually inspected them daily for signs of anorexia, apathy/lack of movement, alopecia, piloerection, porphyrin staining, and dehydration.
Animal Welfare
The Johns Hopkins University Animal Care and Use Committee approved this study. The care and use of the rats conformed to the National Institutes of Health's Guide for the Care and Use of Laboratory Animals (Committee for the Update of the Guide, 2011).
Data Transformation and Statistical Analyses
Because a number of our dependent variables were not normally distributed, we log 10 transformed the 50% PWT values that we obtained via VFH testing as well as the baseline and post-EPM corticosterone levels (Mills et al., 2012) . We used IBM SPSS Statistics 20 to analyze the data. Our analysis plan included descriptive statistics of 50% PWT, baseline and post-EPM corticosterone levels, and body weight and repeated measures analysis of variance (RMANOVA) with Fisher's least significant difference (LSD) test to determine the differences in 50% PWT group means. Our RMANOVA models were constructed to allow us to determine the main and interactive effects of sex, strain, and drug by accumulative dose (4 mg/kg, 8 mg/kg, and 12 mg/kg as well as after the two, 7-day intercycles [7 days after accumulative doses of 4 mg/kg and 8 mg/kg and 7 days after receipt of 12 mg/kg accumulative]) to determine the accumulative and sustained effects of PAC on mechanical hypersensitivity. We conducted Mauchly's test to confirm the assumption of sphericity. When we noted sex differences within rat strain, we constructed ANOVA models to determine the main and interactive effects of sex and PAC on 50% PWT. Finally, we constructed ANOVA models to determine the main and interactive effects of sex and strain on baseline and post-EPM corticosterone. We used a p value of .05 to determine statistical significance.
Results

Accumulative Effects of PAC on Mechanical Hypersensitivity
The accumulative effects of PAC resulted in a significant reduction in 50% PWT (i.e., greater mechanical hypersensitivity), F(1, 80) ¼ 50.77, p ¼ .000. There was a significant strainby-drug interaction, F(2, 79) ¼ 4.75, p ¼ .011, such that SD rats exhibited significantly greater PAC-induced mechanical hypersensitivity compared to F344 rats. The mechanical hypersensitivity of the LEW rats was not significantly different from the SD or F344 rats ( Figure 2 ). We noted apparent within-strain sex differences among PAC-injected F344 and LEW rats early in the protocol. In order to delve deeper into strain-specific responses to PAC, we conducted within-strain RMANOVA with LSD. Following 4 mg/kg accumulative dosing, the PAC-injected female LEW and male F344 rats exhibited significantly greater mechanical hypersensitivity compared to their within-strain counterparts (p < .01 for both; Figure 3 ). There were no statistically significant differences after 8 mg/kg or 12 mg/kg accumulative. We found no sex differences in 50% PWT in the PAC-injected SD rats. Figure 2 depicts the mean (+ standard error of the mean [SEM]) 50% PWT by strain by drug at the conclusion of the active drug phase of each cycle of PAC, and Figure 3 depicts the mean (+ SEM) 50% PWT by sex by strain by drug.
The Sustained Effects of PAC on Mechanical Hypersensitivity
The sustained effects of PAC resulted in significant reductions in 50% PWT, F(1, 80) ¼ 9.53, p ¼ .003, among the LEW and SD rats (Figure 4) . At the conclusion of the recovery weeks, PAC-injected F344 rats exhibited 50% PWTs that were statistically indistinguishable from those of their VEH-injected counterparts, F(1, 28) ¼ 1.84, p ¼ .188. There were significant interaction effects, including sex-by-strain, F(2, 79) ¼ 3.34, p ¼ .041, such that female LEW rats exhibited significantly reduced 50% PWT compared to their opposite-sex counterparts ( Figure 5 ). There was a significant strain-by-drug interaction, F(2, 79) ¼ 7.35, p ¼ .001: PAC-injected SD rats (both sexes pooled) exhibited significantly reduced 50% PWT compared to PAC-injected F344 rats but not PAC-injected LEW rats. Figure 3 depicts the mean (+ SEM) 50% PWT by strain by drug at 7 days after the conclusion of the active drug phase of each cycle of PAC.
We also looked at within-strain responses to PAC. After the first recovery period (7 days after PAC 4 mg/kg accumulative), PAC-injected female LEW and female F344 rats exhibited significantly greater mechanical hypersensitivity compared to their male counterparts in the same strain (p < .05 and p < .05, respectively; Figure 5 ). After the second recovery period (7 days after PAC 8 mg/kg accumulative), PACinjected male SD rats exhibited significantly greater mechanical hypersensitivity compared to PAC-injected female SD rats (p ¼ .05; Figure 5 ). By the conclusion of the protocol (7 days after PAC 12 mg/kg accumulative), there were no sex differences in mechanical sensitivity among PAC-injected rats. Figure 5 depicts the mean (+ SEM) 50% PWT by sex by strain by drug.
HPA Axis Stress Responsivity
There were significant sex differences in baseline plasma corticosterone levels, with male rats exhibiting significantly lower levels than female rats, but there were no strain differences in these levels. Consistent with what Sternberg et al. (1992) reported, there were significant strain differences in poststress plasma corticosterone levels, with the LEW rats exhibiting significantly lower levels compared to the F344 (p ¼ .000) and SD (p ¼ .015) rats. The SD rats exhibited a nonsignificant trend for lower poststress plasma corticosterone levels compared to the F344 rats (p ¼ .08). As with the baseline plasma corticosterone levels, male rats exhibited significantly lower poststress plasma corticosterone levels than female rats (p ¼ .028). Figure 6 depicts mean (+ SEM) baseline and poststress plasma corticosterone levels by strain and sex.
EPM Indices
There were significant strain differences in EPM behavioral indices. The LEW rats exhibited significantly more closedarm entries than the F344 or SD rats (6 vs. 4 and 3, respectively), F(2, 64) ¼ 4. 
Animal Health Throughout the PAC Protocol
The rats tolerated the PAC injections without exhibiting adverse effects. None of the rats exhibited piloerection, porphyrin staining, alopecia, loss of muscle tone, or significant weight loss. Male and female LEW and SD rats exhibited weight gain during the PAC protocol. F344 rats exhibited a negligible weight reduction (<5%) during the active drug phase, which was not statistically significant.
Discussion
This study is among the first to employ a clinically relevant, longitudinal chemotherapy protocol with male and female F344, LEW, and SD rats, known to differ in HPA axis stress responsivity, to determine whether there are sex or HPA axis stress responsivity differences in PAC-induced mechanical hypersensitivity. We hypothesized that the PAC-injected female F344 rats would exhibit significantly greater mechanical hypersensitivity than male rats of the same strain and female and male LEW and SD rats, but our results did not fully support this hypothesis. Our results with respect to sex differences in PAC-induced mechanical hypersensitivity were mixed, somewhat strain specific, and apparent only during the early phase of the PAC protocol. The female LEW and male F344 rats, known for their HPA axis hypo-and hyperresponsivity, respectively, demonstrated significantly greater PACinduced mechanical hypersensitivity after 4 mg/kg accumulative dose compared to their within-strain opposite-sex counterparts. The PAC-injected female LEW rats continued to exhibit significantly greater mechanical hypersensitivity, compared to their male counterparts, at the conclusion of the first recovery period, whereas the male F344 rats recovered to baseline 50% PWT values. Further preclinical studies are warranted to help illuminate the relationships among sex, HPA axis stress responsivity, and CIPN.
Our results suggest that HPA axis stress responsivity may differentially affect PAC-induced mechanical hypersensitivity but not in the direction that we hypothesized. Over the course of the PAC protocol, the outbred SD rat strain, known for expressing a moderate HPA axis stress response, demonstrated significantly reduced 50% PWT, which was most prominent at 7 days after the accumulative receipt of 12 mg/kg (Figure 3) . The F344 strain, compared to the LEW and SD strains, was seemingly resilient against the effects of PAC on mechanical sensitivity outcomes (Figures 2 and 3) . In exploring the raw data, we noted that, after accumulative doses of 4 mg/kg, 8 mg/kg, and 12 mg/kg, 36-50% of PAC-injected F344 rats exhibited 50% PWT ! 10 g, the baseline threshold that all rats needed to achieve to enter the study. These data are in marked contrast with those of the PAC-injected LEW and SD rats, in which 15-20% exhibited 50% PWT ! 10 g at those same points of the study trajectory. Emerging evidence suggests that inflammation may play a role in PAC-induced mechanical hypersensitivity (Carozzi, Canta, & Chiorazzi, 2015; Ledeboer et al., 2007) . Prior research has demonstrated that the LEW rats are more susceptible to inflammatory-based conditions in comparison to F344 rats, which are relatively resilient to them (Sternberg et al., 1992) . Thus, it seems plausible that strain-related differences in response to inflammation may have also contributed to this finding.
Our findings specific to relative resistance of the F344 strain to neuropathic pain are consistent with other strain comparisons using other models of neuropathic pain. For example, following partial sciatic nerve ligation (PSNL) in male LEW and F344 rats, the LEW rats exhibited significantly increased mechanical hypersensitivity, while the F344 rats did not (Fecho & Valtschanoff, 2006) . Additionally, following chronic constriction injury (CCI) of the sciatic nerve of male F344, LEW, and SD rats, Herradon and colleagues (2007) reported that, compared to baseline, all rats exhibited significant, ipsilateral mechanical hypersensitivity 7 days post-CCI. However, by 28 days post-CCI, only the F344 rats demonstrated 50% PWT that were statistically comparable to their baseline, pre-CCI values. The authors did not report obtaining 50% PWT values at any other time point post-CCI. Shir and colleagues (2001) performed PSNL on male rats from seven different strains, including F344, LEW, and SD. They observed significantly greater mechanical hypersensitivity in the SD rats compared to the F344 rats, with PWTs of 6 g versus 11 g, respectively, and the LEW rats exhibited a PWT of 7 g.
Other studies have had contrary findings. Rode and colleagues (2007) employed the spared sciatic nerve injury model in male SD, LEW, and F344 rats and reported that the F344 rat strain exhibited greater mechanical hypersensitivity at 7, 14, and 30 days postinjury. We recently employed the sciatic inflammatory neuritis model with male and female F344, LEW, and SD rats, in which we infused daily doses of zymosan (a 25-mg loading dose on Day 1 and 2 mg doses on Days 2-9) to model an initial pain insult and subsequent subthreshold pain insults (Page et al., 2014) . Compared to the SD rats, LEW rats exhibited significantly greater ipsi-and contralateral mechanical hypersensitivity early in the protocol, whereas the F344 rats did not exhibit significantly greater ipsilateral mechanical hypersensitivity until the latter phase of the protocol. Central effects, reflected by significantly greater contralateral mechanical hypersensitivity, developed in the LEW and F344, but not the SD, rats from Days 7 through 10 (end of the protocol).
It is plausible that the F344 strain's reduced susceptibility to mechanical hypersensitivity relative to a neuropathic model of pain may be attributable to a cascade of effects related to HPA axis stress hyperresponsivity. These effects include increased release of corticotropin-releasing hormone (CRH) and its influence on the immune response (Webster et al., 2002) , the release of pro-opiomelanocortin from the anterior pituitary resulting in increased levels of circulating endorphins, and activation of the sympathetic nervous system and the subsequent release of epinephrine and norepinephrine. This multisystem stress response initiates a host of downstream effects that assist the organism in mobilizing requisite physiologic resources for the ''fight or flight'' response. CRH-induced analgesia is not attenuated by naltrexone pretreatment (Yarushkina, Bagaeva, & Filaretova, 2011) , suggesting that there are mechanisms beyond the endogenous opioid system influencing analgesia, such as glucocorticoids or the noradrenergic system, which are involved in descending pain modulation.
Another avenue through which the F344 strain's reduced susceptibility to the effects of PAC might also include brainderived neurotrophic factor (BDNF), which is involved in nerve cell maintenance and repair. Among the LEW, F344, and SD rats that underwent the sciatic nerve CCI, only the nerveinjured F344 rats exhibited statistically significant upregulation of BDNF messenger RNA in the dorsal root ganglia, compared to controls (Herradon et al., 2007) . It is clear that these interacting systems complicate the relationship between nerve perturbation and mechanical hypersensitivity. Of great interest are the paradoxical effects of BDNF on pain. Miki and colleagues (2000) employed L5, L6 spinal nerve ligation to induce mechanical hypersensitivity in male SD rats and then infused BDNF ip in doses that ranged from 0.5 to 20 mcgm/hr. Lower doses of BDNF resulted in reduced sensitivity to pinprick, whereas the higher dose resulted in hyperalgesia. The scope of the present study precluded our ability to determine whether CRH and/or BDNF were risk or resilience factors for PACinduced mechanical hypersensitivity. Also, we did not capture data on patency of the HPA axis negative feedback loops. Thus, we only know the responsiveness of the corticosterone response and not the duration for which the heightened corticosterone levels were sustained. Further preclinical research is warranted to elucidate the role(s) of the HPA axis, the noradrenergic system, and sex hormones (organizational and activational) in PAC-induced mechanical hypersensitivity.
Our results related to strain differences in HPA axis stress responsivity were consistent with the work by Sternberg and colleagues (1992) , in which rats of the F344 strain exhibited significantly amplified HPA axis stress responsivity when compared with those of the LEW strain. Others have also reported this strain difference in HPA axis stress responsivity (Grota, Bienen, & Felten, 1997; Page et al., 2014) . We also found strain and sex differences in behavioral indices while the rats freely explored the EPM, and rats of the LEW strain exhibited behaviors that translated to being more risk aversive. Although the risk-aversive behaviors exhibited by rats of the LEW strain were not consistent with their attenuated corticosterone response to the EPM exposure, these findings are consistent with the HPA axis stress responsivity and EPM behavioral indices other researchers have reported (Cohen et al., 2006) , including our previous findings that female LEW rats exhibited more open-arm entries and spent more time on the open arms than their male counterparts (Ramos, Berton, Mormède, & Chaouloff, 1997) .
Although there is ample clinical evidence to support the assertion that females are predisposed to conditions associated with pain and have greater pain sensitivity, clinical researchers have not reported sex differences in PAC-induced neuropathic pain. Studies of PAC-induced neuropathy have included persons undergoing adjuvant chemotherapy for ovarian, breast, lung, and prostate cancers, but the vast differences in the chemotherapy protocols (dose intensity, elapsed time per infused dose, and total dose) for these cancer types add to the complexity of making meaningful, across-study comparisons of neuropathy prevalence and severity.
When persons have HPA axis hyperactivity due to nonfunctioning negative feedback loops, they are subjected to sustained and amplified exposure to cortisol (hypercortisolemia). Clinical conditions associated with HPA axis hyperactivity include Cushing's syndrome, depression, anxiety/panic disorders, hypertension, cardiovascular disease, obesity, and type 2 diabetes (Forshee, Clayton, & McCance, 2010; Goel, Workman, Lee, Innala, & Viau, 2014) . Hyperactivation of the HPA axis may also result in suppressed release of growth hormone, thyroid-stimulating hormone, and sex hormones (Harris, 2014) . Emerging evidence suggests that insomnia may be the result of HPA axis hyperarousal (Basta, Chrousos, Vela-Bueno, & Vgontzas, 2007) . Receipt of a cancer diagnosis is a stressful life event that disrupts usual roles, role responsibilities, and leisure time activities. Persons diagnosed with cancer contend with many challenges, such as a potentially lifethreatening illness, loss of employment or need to take unpaid leave, and fears related to unintended effects of life-saving treatments. These stressors can activate the HPA axis over prolonged periods of time, resulting in heightened cortisol levels. Oncology providers typically focus their concerns on attaining the curative goals of adjuvant therapy while monitoring for dose-limiting side effects. However, these providers also need to recognize that the myriad stressors associated with cancer and its treatment activate the HPA axis and result in a cascade of biological consequences, such as increased cortisol, which may precipitate and/or perpetuate adverse consequences of chemotherapy.
In conclusion, our findings suggest that moderate HPA axis stress responsivity may confer additional risk for PAC-induced mechanical hypersensitivity and that early in the treatment trajectory, sex may also confer additional risk for PAC-induced mechanical hypersensitivity. Although this study was conducted under controlled conditions using a rat model, the results may have clinical implications for the therapeutic regimen and/or long-term pain outcomes. Neuropathic pain is a dose-limiting and dose-delaying side effect of PAC that may persist in humans long after therapy is completed. Elucidating the risk and resilience factors in the development of this painful consequence of PAC therapy may be useful in helping clinicians identify persons who may be at increased risk for developing it.
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